Rock Creek Pharmaceuticals (RCPIQ) Stock Price, News & Analysis

Company Overview

Rock Creek Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on the discovery and development of innovative protein and peptide‐based therapeutics. Headquartered in Kansas, the company concentrates its efforts on addressing unmet medical needs in oncology and inflammatory diseases by leveraging proprietary platforms for targeted delivery and immune modulation. Rock Creek’s R&D team works to identify novel biomarkers and optimize therapeutic candidates through iterative preclinical evaluation and strategic partnerships.

The company’s product pipeline comprises a range of recombinant proteins and peptides designed to enhance anti‐tumor activity and regulate immune responses. Lead programs are advancing through preclinical toxicology and early‐phase clinical trials, with a particular emphasis on solid tumors and autoimmune conditions. By combining structure‐guided design with advanced formulation technologies, Rock Creek aims to develop therapies that offer improved safety profiles and greater efficacy compared to existing standards of care.

Founded in 2018, Rock Creek Pharmaceuticals has built a network of academic and industry collaborators across North America and Europe. The company operates state‐of‐the‐art research laboratories and GMP‐compliant manufacturing facilities to support both early discovery and scalable production. Through these capabilities, Rock Creek seeks to move candidates efficiently from bench to bedside while maintaining rigorous quality and regulatory standards.

Rock Creek’s leadership team brings together seasoned drug developers, immunologists and translational scientists with a track record of advancing biologics through clinical proof of concept. Guided by an experienced board of directors, the company pursues a balanced strategy of internal innovation and external alliances to maximize the potential of its therapeutic candidates and deliver value to patients and stakeholders alike.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RCPIQ Stock Analysis - Frequently Asked Questions

How do I buy shares of Rock Creek Pharmaceuticals?

Shares of RCPIQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:RCPIQ
• Previous Symbol: NASDAQ:RCPI
• CIK: 776008
• Web: www.rockcreekpharmaceuticals.com
• Phone: (844) 727-0727
• Fax: 302-636-5454
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A